+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Glaucoma

  • ID: 4421396
  • Report
  • February 2021
  • Region: Global
  • 47 Pages
  • Pharma Intelligence
Definition

This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were 99.7 million prevalent cases of glaucoma in adults aged 40 years and older worldwide, and forecasts that number to increase to 119.4 million prevalent cases by 2028.
  • Africa is estimated to have the highest disease prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).
  • The majority of approved drugs in the glaucoma space target beta adrenergic receptors or the prostaglandin F receptor. Almost all of these approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival or oral formulations.
  • The highest proportion of industry-sponsored drugs in active clinical development for glaucoma are in Phase II, with only one drug in the NDA/BLA phase.
  • While a small number of mid-to-late-stage drugs in the glaucoma space are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The largest number of drugs in mid-to-late-stage development for glaucoma are administered via the intraocular/subretinal/subconjunctival route.
  • High-impact upcoming events for drugs in the glaucoma space comprise topline Phase II trial results for GAL-101, topline Phase III trial results for NCX 470, and an expected PDUFA date for DE-117.
  • The overall likelihood of approval of a Phase I glaucoma/ocular hypertension (ophthalmology) asset is 4.9%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for glaucoma have been in the late phases of development, with 59% of trials in Phase III-IV, and 41% in Phase I-II.
  • The US has a substantial lead in the number of glaucoma clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the glaucoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for glaucoma, with 156 trials.
  • Novartis leads industry sponsors with by far the highest overall number of clinical trials for glaucoma, followed by AbbVie
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Eye drops
  • Oral medications
  • Intraocular implants
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • AKB-9778 for Glaucoma (December 11, 2020)
  • Nyxol for Glaucoma (November 7, 2019)
  • NCX 470 for Glaucoma (October 2, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Phesgo & Roclanda Among New Winners At EMA
  • Allergan’s Ophthalmic Implant Technology Gets Nod For Durysta
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Upjohn To Divest Three In Australia To Complete On Viatris
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of glaucoma, 2019–28
Figure 2: Overview of pipeline drugs for glaucoma in the US
Figure 3: Pipeline drugs for glaucoma, by company
Figure 4: Pipeline drugs for glaucoma, by drug type
Figure 5: Pipeline drugs for glaucoma, by classification
Figure 6: AKB-9778 for Glaucoma (December 11, 2020): Phase II - OHT/OAG
Figure 7: Nyxol for Glaucoma (November 7, 2019): Phase II - ORION-1
Figure 8: NCX 470 for Glaucoma (October 2, 2019): Phase II - Dolomites
Figure 9: Key upcoming events in glaucoma
Figure 10: Probability of success in the glaucoma/ocular hypertension (ophthalmology) pipeline
Figure 11: Clinical trials in glaucoma
Figure 12: Top 10 drugs for clinical trials in glaucoma
Figure 13: Top 10 companies for clinical trials in glaucoma
Figure 14: Trial locations in glaucoma
Figure 15: Glaucoma trials status
Figure 16: Glaucoma trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of glaucoma, 2019–28
Table 2: Prevalence proportions in glaucoma, 2019–28
Table 3: Marketed drugs for glaucoma
Table 4: Pipeline drugs for glaucoma in the US
Table 5: AKB-9778 for Glaucoma (December 11, 2020)
Table 6: Nyxol for Glaucoma (November 7, 2019)
Table 7: NCX 470 for Glaucoma (October 2, 2019)
Table 8: Historical global sales, by drug ($m), 2015–19
Table 9: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll